TB-500 results: what the actual research shows

Last updated 2026-07-25

What is TB-500, and is it the same thing as thymosin beta-4?

TB-500 is a synthetic peptide marketed as a version of an active region of thymosin beta-4 (Tβ4), the naturally occurring 43-amino-acid protein found in almost every mammalian cell. They are related, but they are not interchangeable terms, and a lot of sloppy retail copy treats them like synonyms. The actual TB-500 product circulating in research contexts is typically the N-terminal acetylated 17-23 fragment of thymosin beta-4, not the full 43-amino-acid protein. A 2012 analytical chemistry paper describes the synthesis and characterization of exactly this fragment, noting it was "identified in TB-500, a product suspected to possess doping potential" ^[1]. That's a meaningfully different molecule than native Tβ4: shorter, synthetic, and structurally distinct even though it shares an active region. If you want the deeper comparison between the full-length peptide and the synthetic fragment sold as TB-500, that's covered on its own on the tb4 peptide vs tb500 page. For a general overview of the peptide itself, see the TB-500 hub page.

Are there any published human clinical trials on TB-500?

No. As of this writing, there is no published human clinical trial that dosed TB-500 in people and measured injury or recovery outcomes. This is the single most important fact for anyone reading marketing claims about it. What does exist, and what recent orthopaedic literature actually cites, is a mix of animal studies, in-vitro wound-healing assays, and analytical chemistry papers built for anti-doping detection rather than efficacy testing. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, including the challenges of translating preclinical peptide data into clinical practice ^[2]. A companion piece in the American Journal of Sports Medicine, framed as a primer for orthopaedic and sports medicine physicians, walks through injectable peptide therapy as a category, again distinguishing between peptides with real trial data and those without ^[3]. A third 2026 paper in Sports Medicine (Auckland) specifically reviews the safety and efficacy of both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, which is the most direct attempt in the recent literature to sort out what's actually been tested versus what's just been marketed ^[4]. None of these papers report human trial data specific to TB-500 producing measured tissue-repair outcomes, because that data doesn't exist yet.

What does the preclinical and in-vitro research on TB-500 actually show?

The most direct TB-500-specific research is a 2024 paper in the Journal of Chromatography B that developed a method (UHPLC-Q-Exactive Orbitrap MS/MS) to simultaneously quantify TB-500 and its metabolites in in-vitro experiments and in rats, then screened the results using in-vitro wound-healing assays ^[5]. This is genuinely useful analytical work: it tells researchers how TB-500 breaks down and gives a lab method for tracking it. But it's a metabolism and detection study, run in cell culture and rodents, not a controlled human injury trial. Read the abstract and you'll see the wound-healing screening is a secondary in-vitro check on the chemistry, not a clinical endpoint. A broader 2026 review in Frontiers in Aging covers therapeutic peptides in gerontology, including mechanisms relevant to tissue repair and healthy aging generally ^[6]. It's useful context on how peptides in this class are thought to work at a cellular level, but again, it's a mechanism review, not a TB-500 human outcomes study. So when you see a claim that "TB-500 research shows faster tendon healing" or similar, ask which study that's actually citing. In almost every case it traces back to animal or in-vitro data, sometimes on native thymosin beta-4 rather than the synthetic TB-500 fragment specifically. That's a real distinction, not a technicality.

Why is so much of the TB-500 literature about drug testing instead of healing?

Because that's where the money and the regulatory pressure actually is. TB-500 is prohibited under WADA rules, and equine and human anti-doping labs have spent over a decade building methods to detect it, which means most of the published, peer-reviewed literature on TB-500 specifically is analytical chemistry aimed at catching it in urine or plasma, not efficacy trials aimed at proving it works. A 2012 paper in the Journal of Chromatography A developed a liquid chromatography-mass spectrometry method to detect TB-500 in equine urine and plasma for doping control ^[7]. A 2013 paper in Analytical and Bioanalytical Chemistry extended similar LC-MS doping control work to seven bioactive peptides in horse plasma, TB-500 among them ^[8]. A 2017 paper in Analytical Biochemistry specifically studied adsorption effects, meaning how TB-500 and a handful of other doping-relevant peptides (Insulin Lispro, Synacthen, GHRP-5) stick to lab surfaces and containers, which matters for accurate detection in doping samples ^[9]. There's also a cluster of methodology papers: one on in-vitro models for metabolic studies of small peptide hormones in sport drug testing ^[10], one on comparing various in-vitro model systems (proteolytic enzymes, human blood serum, liver and kidney microsomes, liver S9 fraction) for metabolizing synthetic doping peptides ^[11], one on solid-phase extraction techniques for small bioactive peptides from human urine ^[12], and one on screening peptides under 2 kDa by direct urine injection with ion mobility mass spectrometry ^[13]. Broader review papers on detecting emerging therapeutics and non-approved drugs in doping controls ^[14] and on detecting peptidic drugs and analogs in sports doping generally ^[15] also reference TB-500 as a case study in the detection challenge, not as a proven therapeutic. Read together, this body of work tells you a lot about how labs find TB-500 in a urine sample. It tells you almost nothing about whether TB-500 measurably speeds tendon or ligament repair in a person.

Is TB-500 banned in sports, and does that affect how the research reads?

Yes. TB-500 is prohibited under the World Anti-Doping Agency's list, which is exactly why so much of the published research is doping-control chemistry rather than clinical trials. Labs building detection methods for equine and human anti-doping programs have a direct incentive to publish that work; nobody has a comparable incentive to fund a large, controlled human efficacy trial for a peptide with no FDA-approved indication. That regulatory reality shapes the evidence base in a way worth being blunt about. If you're an athlete under any testing authority, WADA-prohibited status alone should end the conversation regardless of what the preclinical data eventually shows. If you're not a tested athlete, the ban doesn't apply to you legally, but it's still a signal that the research incentives here run toward detection, not proof of benefit.

How does TB-500 fit into the FDA's compounding rules?

TB-500 does not appear on either FDA bulks list that governs compounding. The 503A Bulks List, at 21 CFR 216.23, and the 503B Bulks List, at 21 CFR 216.24, are the FDA's formal registries of bulk drug substances that compounding pharmacies may legally use ^[16][17]. Neither currently includes TB-500. Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, sets the legal framework under which a licensed pharmacist or physician may compound a drug for an identified individual patient based on a valid prescription, generally requiring the bulk substance to appear on FDA's approved list or otherwise meet specific criteria ^[18]. FDA maintains its own guidance page explaining how substances get nominated and evaluated for the 503A bulk list ^[19], and a running current list of substances nominated for compounding use, which reviewers can check directly ^[20]. This matters practically because a peptide's absence from an approved bulks list changes what legitimate, provider-reviewed access can look like. It's also worth checking Drugs@FDA, the FDA's database of approved drug products, which confirms TB-500 has no FDA-approved indication for any use ^[21]. None of this is a judgment about the biology. It's a statement about the regulatory box the compound currently sits in.

Can you buy TB-500 as its own product?

No, not through any legitimate, provider-reviewed channel. TB-500 in that context is dispensed only as part of a BPC-157/TB-500 blend, not as a standalone SKU. Anyone advertising pure, isolated TB-500 for sale outside a research-chemical gray market is not describing how compounding pharmacies that work with prescribing providers actually dispense it. The practical reason for the blend approach is that BPC-157 and TB-500 are commonly paired in the peptide research community for tissue repair purposes, and providers who work with a compounding pharmacy on this typically write for the combination rather than either peptide alone. If you're trying to understand sourcing options and what a provider-reviewed route actually looks like, the TB-500 for sale page walks through that in detail.

Why are BPC-157 and TB-500 usually paired?

Because they're thought to work through different, potentially complementary mechanisms, both associated with tissue repair processes but not documented as substitutes for each other in the human trial sense, since neither has human trial data of the kind that would let you make a precise comparative claim. BPC-157 is a synthetic peptide derived from a partial sequence found in human gastric juice, studied mostly in animal models for gut, tendon, and ligament repair. TB-500 (or native thymosin beta-4, depending on the study) is studied mostly for cell migration and actin regulation relevant to wound healing. The pairing logic in the peptide community rests on the idea that these different mechanisms might work together, but that logic is extrapolated from separate animal and in-vitro literatures on each peptide, not from a combined trial testing the pair against a control. This is exactly the kind of claim where honesty matters more than enthusiasm. Nobody has run a randomized trial pairing BPC-157 and TB-500 in humans and comparing it to either alone or to placebo. If you find a source claiming otherwise, ask for the citation.

What do dosing protocols for TB-500 actually rest on?

They rest on user-reported convention and preclinical dosing schedules from animal studies, not on a human dose-finding trial. That's an important distinction from, say, an FDA-approved drug where dosing comes from phase 1 and phase 2 trials that specifically map dose to blood levels and outcomes. Because there's no human trial establishing a dose-response relationship for TB-500, any specific number you see (milligrams per week, injection frequency, loading phase versus maintenance phase) is coming from either animal study extrapolation or from informal community consensus, not from controlled human data. If you're looking at practical protocols, the TB-500 how to inject guide and the TB-500 injection sites guide cover administration mechanics, and the TB-500 cycle length page covers how long research protocols typically run. All of these should be read with the understanding that they describe common practice, not clinically validated dosing.

Table: what kind of evidence actually exists for TB-500

The pattern in that table should be the main takeaway. There's a real research literature. It's just concentrated in chemistry and detection, not in the clinical outcomes people actually care about.

What should someone researching TB-500 actually take away from this?

Treat every efficacy claim as preclinical until proven otherwise, because right now, that's exactly what it is. The honest summary of the record: TB-500 has real published chemistry, real animal and in-vitro wound-healing screening, and a growing body of orthopaedic review literature that discusses it cautiously alongside other peptides lacking human trial data ^[2][3][4]. It does not have a published human clinical trial measuring injury recovery outcomes. If you're an athlete under any testing authority, the WADA-prohibited status is the deciding fact, full stop. If you're evaluating this as a research subject or considering a provider-reviewed route, know going in that TB-500 is never sold or dispensed as a standalone product through legitimate compounding channels; it comes as part of a BPC-157/TB-500 blend, and any provider worth working with should be upfront about the state of the human evidence rather than overselling animal data as if it settles the question.

Frequently asked questions

Has TB-500 been tested in human clinical trials?

No published human clinical trial has dosed TB-500 and measured injury or recovery outcomes. The existing literature is animal studies, in-vitro wound-healing assays, analytical chemistry for detection, and review articles that discuss TB-500 alongside other unapproved peptides without new human trial data of their own.

Is TB-500 the same as thymosin beta-4?

No. Native thymosin beta-4 is a full 43-amino-acid protein found naturally in mammalian cells. TB-500 is generally the synthetic, N-terminal acetylated 17-23 fragment of that protein, a related but structurally distinct and shorter molecule studied separately in the analytical chemistry literature.

Why is most TB-500 research about drug testing instead of healing?

Because anti-doping labs have a strong incentive to build detection methods for a WADA-prohibited substance, while no comparable funding exists for large human efficacy trials on an unapproved peptide. That's why papers on LC-MS detection in urine and plasma outnumber papers on clinical outcomes by a wide margin.

Is TB-500 banned by WADA?

Yes. TB-500 is prohibited under World Anti-Doping Agency rules, which is also why so much of the peer-reviewed literature on it comes from equine and human doping-control laboratories developing detection methods rather than from clinical research groups.

Can I buy TB-500 by itself?

Not through a legitimate, provider-reviewed channel. It is dispensed only as part of a BPC-157/TB-500 blend, not as a standalone product. Any source claiming to sell pure, isolated TB-500 outside that context isn't describing how compounding pharmacies that work with prescribing providers actually handle it.

Is TB-500 on the FDA's approved bulk drug substances list?

No. TB-500 does not appear on the 503A Bulks List (21 CFR 216.23) or the 503B Bulks List (21 CFR 216.24), the two FDA registries that govern which bulk substances compounding pharmacies may legally use. It also has no listing in Drugs@FDA as an approved drug product.

What does the 2024 TB-500 metabolite study actually show?

A 2024 paper in the Journal of Chromatography B developed a mass spectrometry method to quantify TB-500 and its metabolites in in-vitro experiments and in rats, then used in-vitro wound-healing assays as a secondary screen. It's a chemistry and metabolism study with a wound-healing check attached, not a human efficacy trial.

Why do people pair BPC-157 with TB-500?

The pairing rests on the idea that the two peptides work through different mechanisms relevant to tissue repair, based on separate animal and in-vitro literatures for each. No published trial has tested the combination directly against either peptide alone or against placebo in humans.

What is the dosing for TB-500 based on if there's no human trial?

Reported protocols come from animal study dosing schedules and informal community convention, not from a controlled human dose-finding trial. There's no established dose-response curve in people, so any specific milligram figure you see should be treated as common practice rather than clinically validated dosing.

Do orthopaedic doctors consider TB-500 a proven treatment?

Recent orthopaedic and sports medicine reviews discuss TB-500 as one of several unapproved peptides used off-label, generally urging caution given the absence of human trial data. It is not treated as a proven treatment in the peer-reviewed orthopaedic literature as of these 2026 reviews.

How is TB-500 detected in doping tests?

Labs use liquid chromatography-mass spectrometry methods, first developed for equine urine and plasma around 2012, later extended to human doping controls with techniques including solid-phase extraction and ion mobility mass spectrometry for small peptides under 2 kDa.

Does TB-500 research apply to humans the same way it applies to rats?

Not necessarily. The 2024 metabolite and wound-healing study was done in rats and in-vitro systems, and peptide metabolism can differ meaningfully across species. Extrapolating rat wound-healing screening results directly to human injury recovery is exactly the kind of overreach the research doesn't support yet.

Sources

1. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500 (Drug Testing and Analysis, 2012): TB-500 as commonly sold corresponds to the N-terminal acetylated 17-23 fragment of thymosin beta-4, a distinct molecule from the full-length native protein
2. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026): Recent orthopaedic review literature covers therapeutic peptides including challenges in translating preclinical peptide data to clinical use
3. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (American Journal of Sports Medicine, 2026): A 2026 primer for orthopaedic and sports medicine physicians reviews injectable peptide therapy as a category, distinguishing peptides with trial data from those without
4. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026): A 2026 review specifically evaluates the safety and efficacy evidence for approved versus unapproved peptide therapies used in musculoskeletal injury and athletic performance contexts
5. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats (Journal of Chromatography B, 2024): This 2024 study developed a mass spectrometry method to quantify TB-500 and its metabolites in rats and in-vitro systems, with wound-healing activity screened in vitro
6. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026): A 2026 review covers mechanisms of therapeutic peptides relevant to tissue repair and healthy aging generally
7. Doping control analysis of TB-500 in equine urine and plasma by LC-MS (Journal of Chromatography A, 2012): A 2012 study developed an LC-MS method to detect TB-500 in equine urine and plasma for doping control purposes
8. Doping control analysis of seven bioactive peptides in horse plasma by LC-MS (Analytical and Bioanalytical Chemistry, 2013): A 2013 paper extended LC-MS doping control detection methods to seven bioactive peptides including TB-500 in horse plasma
9. Adsorption effects of the doping relevant peptides Insulin Lispro, Synacthen, TB-500 and GHRP-5 (Analytical Biochemistry, 2017): A 2017 study examined how TB-500 and other doping-relevant peptides adsorb to lab surfaces, affecting accurate detection in doping samples
10. In vitro models for metabolic studies of small peptide hormones in sport drug testing (Journal of Peptide Science, 2015): This paper reviews in-vitro model systems used to study metabolism of small peptide hormones including TB-500 for sport drug testing
11. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides (Journal of Proteomics, 2016): A 2016 study compared enzyme, serum, and microsome-based in-vitro systems for modeling synthetic doping peptide metabolism
12. Solid-phase extraction of small biologically active peptides from human urine (Drug Testing and Analysis, 2016): A 2016 paper describes solid-phase extraction techniques used to isolate small bioactive peptides like TB-500 from human urine for doping analysis
13. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection and ion mobility MS (Journal of Separation Science, 2016): This method paper expands screening for small peptides under 2 kDa, relevant to detecting TB-500 fragments, using direct urine injection and ion mobility mass spectrometry
14. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls (Journal of Pharmaceutical and Biomedical Analysis, 2014): A 2014 review covers analytical approaches for detecting emerging, non-approved therapeutics including peptides like TB-500 in human doping controls
15. Detecting peptidic drugs, drug candidates and analogs in sports doping (Expert Review of Proteomics, 2014): A 2014 review discusses the current status and future direction of detecting peptidic drugs and analogs, including TB-500, in sports doping
16. FDA, 21 CFR 216.23, the 503A Bulks List: TB-500 does not appear on the FDA's 503A Bulks List governing which bulk substances compounding pharmacies may use under section 503A
17. FDA, 21 CFR 216.24, the 503B Bulks List: TB-500 does not appear on the FDA's 503B Bulks List governing bulk substances usable by outsourcing facilities
18. 21 U.S.C. 353a, pharmacy compounding: Section 503A of the FD&C Act sets the legal framework under which compounded drugs must generally use bulk substances from FDA's approved list
19. FDA, bulk drug substances used in compounding under section 503A: FDA's guidance page explains the process by which bulk substances are nominated and evaluated for the 503A compounding bulks list
20. FDA, bulk drug substances nominated for use in compounding (current list): FDA maintains a running current list of bulk drug substances nominated for compounding use, which can be checked for TB-500's status
21. Drugs@FDA, FDA-approved drug products database: TB-500 has no FDA-approved indication for any use, confirmed by absence from the Drugs@FDA database